TIAA CREF Investment Management LLC raised its stake in shares of Glaukos Corporation (NYSE:GKOS) by 17.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 146,397 shares of the medical instruments supplier’s stock after purchasing an additional 22,002 shares during the quarter. TIAA CREF Investment Management LLC owned 0.43% of Glaukos Corporation worth $6,071,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Parametric Portfolio Associates LLC increased its holdings in shares of Glaukos Corporation by 39.1% during the 1st quarter. Parametric Portfolio Associates LLC now owns 61,561 shares of the medical instruments supplier’s stock worth $3,158,000 after purchasing an additional 17,313 shares during the period. Peregrine Capital Management LLC bought a new position in shares of Glaukos Corporation during the 2nd quarter worth about $13,645,000. OppenheimerFunds Inc. bought a new position in shares of Glaukos Corporation during the 1st quarter worth about $8,419,000. Alliancebernstein L.P. increased its holdings in shares of Glaukos Corporation by 26.7% during the 2nd quarter. Alliancebernstein L.P. now owns 1,636,621 shares of the medical instruments supplier’s stock worth $67,871,000 after purchasing an additional 344,739 shares during the period. Finally, Prudential Financial Inc. bought a new position in shares of Glaukos Corporation during the 1st quarter worth about $204,000.

Several research analysts have recently issued reports on GKOS shares. Piper Jaffray Companies restated a “buy” rating and set a $56.00 price objective on shares of Glaukos Corporation in a report on Thursday, August 3rd. Zacks Investment Research upgraded shares of Glaukos Corporation from a “hold” rating to a “buy” rating and set a $45.00 price objective on the stock in a report on Friday, July 14th. Stephens restated a “buy” rating and set a $47.00 price objective on shares of Glaukos Corporation in a report on Friday, September 15th. BidaskClub upgraded shares of Glaukos Corporation from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, Cantor Fitzgerald restated a “buy” rating and set a $60.00 price objective (up previously from $54.00) on shares of Glaukos Corporation in a report on Thursday, September 14th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. Glaukos Corporation has an average rating of “Buy” and an average price target of $49.86.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/10/15/tiaa-cref-investment-management-llc-boosts-stake-in-glaukos-corporation-gkos.html.

Shares of Glaukos Corporation (NYSE:GKOS) opened at 33.33 on Friday. The company’s market cap is $1.15 billion. The company has a 50-day moving average of $33.87 and a 200-day moving average of $33.87. Glaukos Corporation has a 1-year low of $28.72 and a 1-year high of $52.49.

In related news, CEO Thomas William Burns sold 73,788 shares of the firm’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $41.36, for a total transaction of $3,051,871.68. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Orbimed Advisors Llc sold 580,200 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $38.73, for a total transaction of $22,471,146.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 980,200 shares of company stock valued at $37,900,263. 16.40% of the stock is currently owned by corporate insiders.

About Glaukos Corporation

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Institutional Ownership by Quarter for Glaukos Corporation (NYSE:GKOS)

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.